Illia Petrov

Insilico Medicine has released benchmarks detailing the timelines and development metrics for 22 preclinical candidate (PCC) nominations achieved between 2021 and 2024. These self-reported metrics offer a view of the company's AI-driven drug discovery (AIDD) workflow—demonstrating an average 13-month timeline to PCC nomination, a reduction from the traditional 2.5- to 4-year process, and validating the efficiency of its approach.

Basetwo, an AI platform for manufacturing engineers, has raised $11.5 million in Series A funding. The funding will support the development of Basetwo’s Physics AI platform, designed to optimize pharmaceutical and chemical manufacturing processes.

Insilico Medicine, a clinical-stage biotechnology company leveraging generative AI for drug discovery, has dosed the first patient in its global Phase I trial of ISM6331, a novel pan-TEAD inhibitor for the treatment of mesothelioma and other solid tumors. The trial, conducted in both China and the United States, aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of ISM6331.

Servier, an international pharmaceutical group, and Google Cloud have announced a five-year extension of their collaboration to integrate AI technologies across Servier's R&D, production, and distribution activities. This partnership aims to address challenges in drug development, which currently takes an average of 15 years, by using AI to analyze large datasets, streamline clinical trials, and optimize drug formulations.

A28 Therapeutics, a clinical-stage biopharmaceutical company, and GATC Health Corp, a developer of AI-driven drug discovery tools, have announced the completion of an AI-based analysis of A28’s lead drug candidate, AT-101. This analysis was conducted to evaluate the drug’s efficacy, safety, and potential off-target effects, with the goal of supporting clinical trial optimization and minimizing development risks. The announcement was made during the J.P. Morgan Healthcare Conference.

Researchers at CCM Biosciences, a New Jersey-based biopharmaceutical company, have reported the discovery of first-in-class compounds designed to restore the activity of SIRT3, a mitochondrial enzyme critical to cellular energy production and aging processes. Published in Physical Review X, this study introduces a novel mechanism of enzyme activation, bypassing the limitations of traditional allosteric modulation methods.

Profluent Bio, a Berkeley-based biotech founded in 2022, and funded with $44 million to date, has released an AI model aimed at advancing the design of CRISPR-Cas gene-editing systems. The company's latest research, published in a preprint on January 6th, 2025, demonstrates how deep learning can be harnessed to expand the genome-editing potential of CRISPR complexes by tailoring their DNA recognition capabilities.

FTI Consulting’s Healthcare & Life Sciences Outlook Survey surveyed 250 U.S.-based decision-makers from corporate communications, investor relations, public affairs, business development, and marketing roles in healthcare and life sciences companies. Conducted online between September 24 and October 9, 2024, the survey provides insights into industry optimism, challenges, and investment priorities.

Just two months after raising $120 million to advance its AI-driven tNova platform and internal immunology programs, Terray Therapeutics has secured a new research partnership with Gilead Sciences. The collaboration focuses on discovering and developing novel small molecule therapies across multiple therapeutic targets identified by Gilead.

Following its recent expansion into Japan, Lantern Pharma has now dosed the first patient in Taiwan as part of its Phase 2 Harmonic clinical trial., evaluating LP-300 in never-smoker non-small cell lung cancer (NSCLC) patients who have relapsed after tyrosine kinase inhibitor (TKI) therapy.